US FDA accepts for review the resubmission of sBLA for Dupixent to treat chronic spontaneous urticaria: Paris Monday, November 18, 2024, 11:00 Hrs [IST] The US Food and Drug Admin ...
A new study published in the journal of Respiratory Medicine showed that patients with type 2 inflammation and chronic ...
Resubmission includes new pivotal data which confirm Dupixent significantly reduced itch and hive activity More than 300,000 people in the U.S. suffer from CSU that is inadequately controlled by ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback